- Stocks
- Healthcare
HKPD
Cellyan Biotechnology Co., Ltd
HKPD
NASDAQ·Healthcare·Medical - Distribution·Mkt cap $1.4M
$0.13
▼ -8.86%
P/E
—
Mkt Cap
$1.4M
52-Wk Range
$0.12–$1.82
52-Week Range
$0.12 - $1.82
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 89.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Cross-border pharmaceutical expertise and regulatory compliance capabilities
- Integrated supply chain infrastructure reducing logistics costs
- Strategic positioning in high-growth Hong Kong-China pharmaceutical corridor
- Digital-first e-commerce distribution model aligned with market trends
Bear Case
1 risk
- High volatility (beta 2.2). Larger-than-normal price swings expected.
Growth
No forward estimates available
Explosive growth in OTC pharmaceutical e-commerce across Asia
Value
Valuation data unavailable
Momentum
Falling
-73.9% over 3m
Quality
Thin
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying HKPD right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Most recent quarter reported revenue of $1.2M (-5% YoY). Reported EPS of -$0.01. Gross margin 5.5%.
Reported EPS · last 4Q
Q4 25
-$0.01
Q2 24
$0.01
Q4 24
$0.01
Q2 23
$0.00
Revenue trend · last 4Q
—
—
+58%
-5%
Q2 23
Q4 24
Q2 24
Q4 25
$894.4K
$1.2M
$1.4M
$1.2M
Margins · last 4Q
Gross
5.5%
Operating
-9.7%
Profit
-9.3%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How HKPD stacks vs Medical - Distribution
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related